Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.
RemeGen Co., Ltd. announced changes to its Nomination Committee, effective May 26, 2025, with Mr. Wang Weidong stepping down and Dr. Su Xiaodi joining as a member. These changes align with the amended Corporate Governance Code and aim to enhance the company’s governance practices, improving board effectiveness and diversity.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative drugs, particularly in the areas of oncology, autoimmune, and ophthalmic diseases.
Average Trading Volume: 9,367,111
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.81B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.